All In Biotech

Drug Trial Radar · NCT07189910

Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

Efficacy and Safety of Glucocorticoids Combined With Recombinant Human Thrombopoietin (rhTPO) Sequential Eltrombopag Olamine for Severe Primary Immune Thrombocytopenia (ITP) in Adults

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Nov 1, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To address the clinical need for improving early response rates, maintaining sustained responses, reducing relapse rates, and minimizing adverse events in the treatment of immune thrombocytopenia (ITP), the investigators developed a comprehensive in-hospital and post-discharge management strategy. In this study, hospitalized participants will receive a 14-day regimen of high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO), followed by a 10-week course of oral eltrombopag olamine dry suspension after discharge. The investigators aim to evaluate the efficacy and safety of this sequential treatment strategy in adult ITP patients.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

  • EltrombopagDrug

    Participants assigned to the observation group will be treated with eltrombopag oral suspension (EPAG-pfos).

  • PlaceboOther

    Participants in the control group will receive a placebo at the same dose, instead of eltrombopag oral suspension (EPAG-pfos).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained response rate (SRR) at 3 months of treatment.Time frame: 3 months of the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wuhan Union Hospital

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.